LYRA — Lyra Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $6.51m
- -$25.23m
- $1.53m
- 48
- 14
- 32
- 22
Annual cashflow statement for Lyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -22.1 | -43.5 | -55.3 | -62.7 | -93.4 |
| Depreciation | |||||
| Non-Cash Items | 1.77 | 2.77 | 6.27 | 3.98 | 29.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.879 | 13.9 | 4.55 | -4.88 | -6.35 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -21.1 | -25.8 | -43.4 | -63.3 | -70 |
| Capital Expenditures | -1.77 | -3.38 | -0.164 | -1.05 | -2.34 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | -64.8 | -11.5 | 82.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.77 | -3.38 | -65 | -12.6 | 80.3 |
| Financing Cash Flow Items | -2.59 | -0.245 | -4.25 | -3.65 | -0.29 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 87.7 | 0.359 | 96.3 | 65.7 | 8.53 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 64.8 | -28.8 | -12.1 | -10.2 | 18.8 |